较低体重与较低脂肪量与两种类风湿关节炎治疗策略的差异应答相关
该研究为RACAT试验和TEAR试验的二次分析,比较甲氨蝶呤应答不足后启动肿瘤坏死因子抑制剂(TNFi)与三联疗法的应答差异。RACAT中正常/体重过低者TNFi优于三联疗法(ACR20 64% vs 23%,p=0.001),超重/肥胖者两策略应答相似(交互p=0.001);TEAR中观察到相似但较弱的趋势(ACR20 67% vs 52%,p=0.05)。
要点
- RACAT中正常/体重过低者TNFi较三联疗法ACR20更高(64% vs 23%,p=0.001)。
- 超重/肥胖者两种治疗策略应答相似(交互p=0.001)。
- RACAT中脂肪因子评分提示较低脂肪量者TNFi应答更优(ACR20 58% vs 37%,p=0.01)。
核心结论
- 较低BMI及基于脂肪因子谱的较低脂肪量与TNFi相比三联疗法更优的应答相关。
- 超重/肥胖参与者中两种治疗之间无差异。
- 结果支持TNFi在正常/体重过低患者中是特别重要的治疗选择,对临床决策和试验设计有启示。
研究设计与样本
- RACAT试验和TEAR试验的二次分析。
- 两项研究均比较以传统改善病情抗风湿药起始(三联疗法)与依那西普联合甲氨蝶呤两种治疗策略。
- RACAT样本量n=306,TEAR样本量n=601。
- 脂肪因子于入组时测定,采用回归分析其与治疗应答的关联,校正年龄、性别、BMI和基线疾病活动度。
主要发现
- RACAT中正常/体重过低者TNFi相比三联疗法获益更多,DAS28变化更大且ACR20应答更高(ACR20:64% vs 23%,p=0.001)。
- RACAT中超重/肥胖者TNFi与三联疗法应答相似(交互p=0.001)。
- TEAR中观察到相似但较弱的模式(ACR20:67% vs 52%,p=0.05)。
- RACAT中与较低脂肪量一致的脂肪因子评分也预测TNFi应答更优(ACR20:58% vs 37%,p=0.01),且模型拟合优于单用BMI。
临床怎么用
- 作者认为结果支持TNFi在正常/体重过低患者中是特别重要的治疗选择,对临床决策和试验设计有启示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response. METHODS: This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the (TEAR) trial. Both studies compared treatment strategies starting with conventional disease-modifying anti-rheumatic drugs (DMARDs) (triple therapy) versus etanercept plus methotrexate. We compared response rates between TNFi and triple therapy among patients with different BMI. Adipokines were measured at enrolment and associations with treatment response were examined using regression, adjusting for age, sex, BMI and baseline disease activity. RESULTS: In RACAT (n=306), participants who were normal/underweight were more likely to benefit from TNFi versus triple therapy, with greater change in Disease Activity Score in 28 and greater ACR20 response (ACR 20: 64% vs 23%, p=0.001). In contrast, overweight/obese participants had similar response to TNFi versus triple therapy (p-for-interaction=0.001). Similarly, but modest patterns were observed in TEAR (n=601; ACR20: 67% vs 52%, p=0.05). In RACAT, adipokine scores consistent with lower adiposity also predicted greater response to TNFi (ACR20: 58% vs 37%, p=0.01) with better model fit compared with BMI alone. CONCLUSIONS: Lower BMI and evidence of lower adiposity based on adipokine profiles were associated with a superior response to TNFi compared with triple therapy. There was no difference between treatments among overweight/obese participants. The results support TNFi being a particularly important therapeutic among normal/underweight patients, with implications for clinical decisions and trial design.
引用
- Baker JF, ODell JR, England BR, et al. Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Ann Rheum Dis. 2024. PMID: 38171598. doi:10.1136/ard-2023-225014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。